3상모집 중
A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age
연구 개요
The purpose of this study is to evaluate the immune response and safety of GSKs investigational varicella vaccine (VNS Vaccine) compared to an already approved varicella vaccine, Varivax (VV), when administered as second dose to healthy children. 3 months after first dose at 12 to 15 months. The study will be conducted in children who have not previously contracted varicella or received a varicella vaccination.
- 스폰서
- 리드: GSK
- 적응증
- Chickenpox
- 중재
- Investigational varicella vaccine, Marketed varicella vaccine, MMR vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
- 목표 등록
- 600명
- 시작일
- 2025-05-15
- 완료(예정)
- 2027-05-03
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.